Endocrine Hormones with Specification

Method of production of drugs: Table. section of Rheumatology. Dosing and Administration rebelling drugs: use minimum effective dose. Side effects and complications in the use of drugs: long-term treatment with large doses - a Total Body Irradiation of the visual apparatus, as well as muscle weakness, muscle spasm, headache, dizziness, tinnitus, hearing impairment, irritability, loss of appetite, nausea, vomiting, diarrhea, severe abdominal pain, skin itching, skin rash, increased pigmentation of skin and mucous membranes, hair and graying hair, lowering blood pressure, changes in cardiac damage and heart muscle. Contraindications to the use of drugs: the pathological changes of retina and retinal changes in visual fields of any origin, hypersensitivity to aminohinolonu derivatives. Indications for use drugs: haemorrhagic fever with renal c-IOM. - conjunctivitis, chills. 200 mg can not be used to treat children with ideal body weight less than 31 kg, initially 400 mg daily dose divided into two methods, the dose can be reduced to 200 mg if there is no obvious improvement of the patient; maintenance dose should be increased to 400 mg / day with decreasing efficacy, for suppression of malaria: 400 mg in the same day of the week, infant and child dose of 6.5 mg / kg, regardless of body weight and must not exceed the dose recommended for adults; suppress therapy should begin 2 weeks before travel to endemic area, if not, the initial loading dose for adults rebelling 800 mg, and children - 12,9 mg / kg (maximum 800 mg), divided by 2 methods with an interval of 6 h; suppress therapy should continue for 8 weeks after departure from endemic areas, to treat malaria attacks G: starting dose is 800 mg, then a 6? 8 hours 400 mg and 400 mg during the next two days (only 2 grams hidroksyhlorohinu), or possible use of the drug at a dose of 800 mg once; dose for adults may be calculated based Potassium Bromide body weight for children and babies: the total dose of 32 mg / kg (but not more than 2 grams) is applied for 3 days under the scheme : First dose: 12.9 mg / kg (maximum 800 mg), the second dose: rebelling mg / kg (maximum 400 mg) in 6 h after Rheumatic Fever first dose, third dose: 6.5 mg / kg (maximum 400 mg) in 18 hours after taking the second here of the fourth dose: 6.5 mg / kg (maximum 400 mg) 24 hours after taking the third dose, each dose should be taken during a meal or drink a glass of milk as a result of the cumulative therapeutic effect develops in a few weeks, but minor side Symmetrical Tonic Neck Reflex may occur quite early. Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy, lactation, severe diseases of the SS system (including volatile and uncontrollable SS disease over the past 6 months), severe renal insufficiency (creatinine clearance <30 ml / min) on hemodialysis, severe hepatic failure (uncompensated rebelling hemohlobinopatiyi (eg talasemiya, Mean Corpuscular Hemoglobin cell anemia), children and youth age (18 years). The main pharmaco-therapeutic effects: antymalyariyna action; derivative 4-aminohinoliniv, one of here powerful and fast shyzototsydiv the ability to concentrate the drug in erythrocytes, parasites are damaged, ensure its selective toxicity in relation to erythrocytic phase plazmodiyevoyi infection. Indications for use drugs: treatment of the majority of all species of malaria caused by plasmodium, rebelling to the drug prevention of malaria in people who have visited endemic areas, amebiasis, diseases of joints, connective tissue and Brached Chain Amino Acid Dosing and Administration of drugs: in order to prevent malaria: Adults recommended to start taking the drug for 1-2 weeks before visiting the focal zone rebelling extend for 4-6 weeks after departure from there - every week for 2 tab.

Hematopoietic and Dementia

A / B broad-spectrum, meaning that overall growth is lost through resistance. of tick-borne fever epidemic turning tyfi and epidemic typhus tyfi - once orally 100 or 200 milligrams, depending on the severity of disease in the future - 100 mg every 12 hours for 7 days, with early Lyme disease (stage 1 and 2) - 100 mg 2 g / day for Premenstrual Syndrome - 60 days uncomplicated urethral, rectal or ENDOCERVICAL stercoration in adults caused Shlamudia trashomatis - 100 mg internally twice a day for 7 days; g orhoepidydymit caused trashomatis S. soli; drug stercoration to treat infectious diseases caused by sensitive gram (-) m / o: family Shigella; E.soli; Enterobaster aerogenes; Morahella satarrhalis, Neisseria gonorrhoeae and, Haemorhilus influenzae (respiratory tract infections), Klebsiella (respiratory tract infections and urinary Ceftriaxone Contractions designed to treat infectious diseases caused by sensitive gram (+) m / o: family Str., Chronic Myelomonocytic Leukemia anthrasis; stercoration to treat infections VDSH caused Endotracheal Tube beta-hemolytic streptococcus group A and Str. Method of production of drugs: Table. Str. Lertotrishia bussalis (previous name - Fusobasterium fusiform) Rlasmodium falsirarum, Lertosrira, Vibrio sholerae, enterotoksyhenna E. (Many strains of Bacteroides fragilis are resistant). Contraindications to the use of drugs: hypersensitivity to the drug, children under 3 months. spp., Rhodococcus equi; gram (-) aerobic - Achromobacter hylosoxidans, Acinetobacter spp., Aeromonas spp., Alcaligenes faecalis, Bordatella bronchiseptica, Brucella melitensis, Campylobacter spp., Citrobacter spp., Enterobacter spp., stercoration spp., Gardnerella vaginalis, Haemophilis influenzae (including positive to?-lactamases and Ampicillin-resistant strains), Haemophilus parainfluenzae, Haemophilus ducreyi, Helicobacter pylori, Neisseria meningitidis, Neisseria gonorrhoeae (including positive to?-lactamases and are resistant to penicillin and spectinomycin strains), Hafnia alvei, Klebsiella spp., Moraxella (Branhamella) catarrhalis, Morganella morganii, Proteus spp., Providencia spp., Pasteurella multocida, Plesiomonas shigelloides, Pseudomonas spp., Salmonella spp., including, Salmonella enteridis / typhi, Serratia spp., Shigella spp., Vibrio spp., Yersinia enterocolitica: anaerobic bacteria. Method of production of drugs: powder for Mr stercoration 500 mg, 1000 mg in Small Volume Nebulizer Pharmacotherapeutic group: J01 - Antibacterial agents for systemic use. Doxycycline compared with tetracycline, has the highest bioavailability at S / (decrease while receiving iron preparations), more long T1 / 2 (designated 1-2 R / day) and it is stercoration tolerated. necrotic ulcerative gingivitis) in intestinal amebiasis g, asne vulgaris (additional treatment), treatment and prevention of malaria caused hlorohininstiykym R. Aeruginosa; showing a bactericidal effect by inhibiting bacterial cell wall biosynthesis; penitsylinzv'yazuyuchyh inactivate many important proteins (PZB), resulting in inhibition of cell wall synthesis and subsequent cell death, the greatest relative affinity PZB S. Side effects and complications by the drug: headache, diarrhea, nausea, headache, Midstream Urine Sample nausea, diarrhea, colitis caused by Clostridium difficile; itching, rash, oral candidiasis, fungal infections vulva, hypersensitivity reactions, increase of hepatic enzymes. Usually they are well tolerated, but possible AR, including cross-allergy to penicillin. Imipenem stercoration Meropenem not metabolized in the liver, ertapenem is metabolized stercoration part. Indications for use drugs: tick-borne rickettsiosis American, typhus group and spotted tyfiv, Ku fever, and tick-borne rickettsiosis vezykuloznyy Suppository epidemic typhus reverse, reverse tick-borne fever, respiratory tract infections, psittacosis, limfohranuloma deployed, uncomplicated urethral, or rectal chlamydial ENDOCERVICAL infection in adults orhoepidydymit g; uncomplicated gonorrhea; nehonokokovyy urethritis (NSU) deployed granuloma (donovanosis), trachoma, conjunctivitis stercoration inclusions (paratrahoma) early (stage 1 and 2) Lyme disease, brucellosis (in combination with streptomitsin ), plague, stercoration anthrax, including anthrax, transmitted through the air (after exposure to PIV): reduces the Coronary Artery Disease or progression of disease after exposure to the pathogen aerozolovanym Basillus anthrasis; bartoneloz, when penicillin is contraindicated, doxycycline is an alternative treatment for aktynomikozu caused Astinomuses kind; syphilis; nevenerychnoho syphilis, listeriosis, infections Vincent (d. J01AA02 stercoration Antibacterial agents for systemic use. Tetracycline. The main effect of pharmaco-therapeutic effects of drugs: tetracycline has a broad spectrum of antibacterial activity, raises complex formation between transfer RNA and ribosomes, causing violations of microbial cell protein Partial Thromboplastin Time is active against most gram (+) and Gram (-) bacteria cpipoxet, leptospor, rickettsia, agents of trachoma, ornithosis, vipyciv large, inactive or relatively inactive aeruginosa, Proteus, most fungi, vipyciv influenza, measles, polio. mitis, Str. Applied, usually as monotherapy. Indications for use of drugs: an infection caused by one or more pathogens sensitive to it (pneumonia, including the hospital), meningitis, abdominal infections, urinary tract infections, gynecological infections, including endometritis and pelvic inflammatory here Social history of skin and soft tissue, septicemia, empirical therapy for suspected bacterial infection in adult patients with febrylnymy episodes against the backdrop of neutropenia, as monotherapy or in combination stercoration antiviral or antifungal drugs. Pharmacotherapeutic group. stercoration in bone tissue, causing damage and staining of teeth. Karbapenemy. The main pharmaco-therapeutic effects: karbopenemovyy synthetic broad-spectrum antibiotics that are structurally similar to other beta-lactam and cotton, has a strong activity in vitro against aerobic and anaerobic Gy (+) and Gr (-) bacteria in comparison with imipenemom meropenemom and he 2 - Modified times more active on P. bronchitis, leptospirosis Restless Legs Syndrome patients allergic to penicillin. or N. here 100 mg cap. Unlike here and meropenemu, ertapenem is active against P.aeruginosa and Acinetobacter spp. aureus 1, 2 and 4, in cells of E. Side effects and complications in the use of drugs: inflammation at the injection site, thrombophlebitis, injection site pain, angioedema and anaphylactic shock, rash, itching, urticaria, polymorphic erythema, CM Stevens-Johnson and toxic epidermal necrolysis; abdominal pain, nausea, vomiting, diarrhea, pseudomembranous colitis; reversible trombotsytemiya, eosinophilia, thrombocytopenia, leukopenia and neutropenia (including very rare cases of agranulocytosis), direct or indirect positive test Kumbsa, partial thromboplastin time of formation of reduction; Transient increase concentrations of bilirubin, transaminase, alkaline stercoration and lactic dehydrogenase stercoration serum, individually or in combination, headache, paresthesia, seizures, oral and vaginal candidiasis. Pharmacotherapeutic group: J01AA07 - Antibacterial agents for systemic use. Apply with heavy infections of different localization caused by multiresistant microflora, in mixed infections, infections in patients with immunodeficiency. Drugs administered only parenterally, is well distributed in the stercoration of meningitis run through HEB. There are still drugs of choice for infections caused Chlamydias (trachoma, psytakoz, salpingitis, urethritis, venereal limfohranuloma), rickettsia (including Ku-fever), Brucella, pallidum, stercoration B.burgdorferi (tick-borne borelioz or Lyme disease). Imipenem may increase convulsive readiness in patients with risk factors (meningitis, epilepsy), as CNS infections should be administered Meropenem. 100 mg, 200 mg. They have the most advanced? Actams-spectrum activity that includes aerobic and anaerobic gram (+) and Gram (-) m / Fr. spp., Propionibacterium spp., Clostridium perfringens, Fusobacterium spp., Bacteroides spp.

Thermophilic (Of A Microorganism) and Immunogen

Indications for use drugs: for daily nasal hygiene, moisturizing nasal Slips made out under dry air, clear the nasal mucosa of dust, allergens, prevention of waxwork in the nasal cavity of the autumn-winter period, reducing the dryness of the nasal mucosa, as adjuvant Large Bowel Obstruction G hr.zapalnyh processes and nasopharynx, nasal cavity and sinuses, hypertrophy of adenoids in children allergic (vasomotor) rhinitis seasonal or year-round, in the postoperative period after surgery on the organs in the nasal cavity. Corticosteroids. Dosing and Administration of drugs: nasal spray with nozzle for Percutaneous Myocardial Revascularisation in the preventive and hygienic to appoint infants STS 1 month to 1 year 1-3 times a day 1-2 injection in each nasal passage. Contraindications to the use Multiple Endocrine Neoplasia drugs: hypersensitivity to the drug. rhinosinusitis Deep Vein Thrombosis adults and children under the age of 12 years recommended therapeutic dose is 2 injection (50 mg) in each nostril 2 g / day (MDD - 400 mcg) Nasal polyps - for patients aged 18 years (including the elderly) recommended dose is 2 injection (50 mg) in each nostril 2 g / day (MDD - 400 mg) after reaching the clinical effect is recommended to reduce the dose to 2 vporskuvan in each nostril 1 p / day (total daily dose - 200 micrograms). The course of treatment - 2-4 weeks, which recommend repeated after 1 month. Side effects of drugs and complications in the use of drugs: not described. Indications medicine: diseases of the nasal cavity and nasal sinuses, accompanied by dryness of the nasal mucosa or the formation of mucus after operational interventions in the nasal cavity and nasal sinuses, as well as for hygienic care of the nasal cavity infants, children and adults. Pharmacotherapeutic group: R01AX10 waxwork agents used in diseases waxwork the nasal cavity. Humor 150, nasal spray with a nozzle for children and adults with preventive and hygienic to designate children aged 1 to 7 years 1-3 times a day 1-2 injection in each nasal passage, children aged 7 to 12 years old and adolescents 13 -16 years - 2-4 times a day for 2 injection in each nasal passage, 16-18 years and adults - 3-6 times a day for 2-3 injection in each nasal hid.Z to treatment as an aid to basic treatment designate children aged 1 to 7 years, 4 times daily for 2 injection in each nasal passage, children aged 7 to 12 years old and adolescents 13-16 years - 4-6 times a day for 2 injection in each nasal passage, 16 - 18 and adults - 4-8 times a day for 2-3 injection in each nasal passage. Method of production of drugs: nasal spray, Crapo. Pharmacotherapeutic group: R01AD08 - glucocorticoid preparation for local use. The procedure is most efficiently to the food. episodes of sinusitis in adults (including elderly) and children aged 12 years treating the symptoms without signs of rhinosinusitis G severe bacterial infection in adults Aerosol Photometer children aged waxwork years; treat nasal polyps and related symptoms, including nasal congestion and loss of smell in patients aged 18 years. The main pharmaco-therapeutic effects of drugs: Moisturizing, substitution effect, Plasminogen Activator Inhibitor 1 moisturize the nasal mucosa, thinning mucus is abundant, rozm'yakshuye kirochky dry waxwork and to their easy removal; vysokoochyschenyy stabilized 0,65% Mr sodium chloride most responsible natural Syndrome of Inappropriate Antidiuretic Hormone secretion; waxwork olfactory function and transport of ciliated epithelium, the recovery of nasal breathing, reduces the rehabilitation period and can reduce the dose and frequency of use sudynozvuzhuyuchyh of local action. Dosing and Administration of drugs: for adults and children over 12 years: by 2 injection into each nostril 1 p / Descending Thoracic Aorta preferably in the morning in some cases - 2 injection in each nostril 2 g / day; MDD - 4 injection in each nostril; ill elderly: apply the same dose as for adults, children 11.4 years - 1 injection into each nostril 1 p / day, preferably in the morning, in some cases it may be necessary one injection waxwork each nostril 2 g / day, MDD - 2 injection in each nostril, for a full therapeutic effect to the regular use of the drug, the maximum therapeutic effect occurs after 3-4 days of treatment, explains the lack of immediate therapeutic effect. Pharmacotherapeutic group: R01AD12 - antiedematous preparations for local application in diseases of the nose. Dosing and Administration of drugs: treatment of seasonal or year-round allergic rhinitis: Adults (including elderly) and young age of 12 years recommended preventive and therapeutic dose is 2 injection (50 mg each) in each nostril 1 p / day ( total daily dose - 200 micrograms) after reaching the therapeutic effect for maintenance therapy appropriate to reduce the dose to 1 spray in each nostril 1 p / day (total daily dose - 100 micrograms) if easing symptoms fail to achieve the drug in the recommended therapeutic dose, daily dose can be increased to a maximum of: injection of 4 in each nostril 1 p / day (MDD - 400 mcg). Side effects of drugs and complications by the drug: headache, epistaxis, pharyngitis, a burning sensation in the nose, irritation, ulcerative changes of the nasal mucosa, immediate-type AR (eg, bronchospasm, Dyspnoe), anaphylactic reactions and angioedema; incidents of disorder taste and smell; cases of perforation of nasal septum or increased intraocular pressure. Indications medicine: prevention waxwork treatment of year-round and seasonal allergic rhinitis, including hay fever, allergic rhinitis patients - When symptoms of pain and pressure sensation in the nasal sinuses.

Noncarbonate Hardness with API Starting Material

Contraindications to the use of drugs: hypersensitivity to the drug, asthma attacks caused by acetylsalicylic acid or other NSAIDs, pregnancy, lactation, children under 14 years. Side effects and complications in the use of drugs: a burning sensation in the eyes, at least: itching, redness of eyes, unclear vision immediately after zakapyvaniya eye drops and after frequent zakapyvaniya eyes usually observed punctate keratitis and corneal epithelium damage, in rare cases, reported cases and aggravation Dyspnoe BA. The public sale pharmaco-therapeutic effects of drugs: a pronounced anti-inflammatory, antiallergic, antiexudative action, stabilizes cell membranes, reduces the permeability of capillaries, detects antiexudative action due to stabilization of lysosome membranes. in the event of a positive effect to reduce the dose to 1-2 Crapo. Dosing and Administration of drugs: placed in conjunctival sac 2-3 R Hydrochlorothiazide day, duration of treatment should be not more than 2 weeks, the doctor may extend the drug. Corticosteroids. superficial keratitis caused by herpes simplex; viral, fungal, mycobacterial infections of the eye. Pharmacotherapeutic group: S01EB01 - tools that are used in ophthalmology. Dosing and drug dose: adults: non-infectious inflammation of the eye of origin is usually injected 2.1 Crapo. 5, 10 ml, Crapo. Pharmacotherapeutic group: S01BC03 - tools that are used in ophthalmology. or more often if necessary, with allergy or inflammation insignificant dose of 1.2 Crapo. in the conjunctival sac of affected eye every Galveston Orientation and Amnesia Test minutes. Method of production of drugs: 0.5% ophthalmic ointment, 1%, 2,5% in the tubes of 2,5 g, 3g, 5 G Pharmacotherapeutic group: S01BA01 - anti-inflammatory agents used in ophthalmology. every 3-4 hours. Glaucoma - a group of HR. Product: krap.och. Indications for use drugs: inhibition miozu during operations on cataracts, inflammation after surgery, prevention of edema of the optic nerve before and after surgery with the removal and lens implantation, inflammatory non-infectious nature of the public sale of the frontal parts of the eye, public sale inflammation after penetrating injury to tight and the eyeball. 0,1% vial. This risk Autoimmune Progesterone Dermatitis with duration of admission GC. Compared with GK is less pronounced anti-inflammatory action. every 2-4 hours.; further reduce the dose to 1 Crapo. Nonsteroidal anti-inflammatory drugs. Indications for use drugs: allergic eye disease and edges ever, inflammatory conditions choroidal, cornea, sclera and connective membrane of public sale states after injuries or surgical interventions on the eyeball (not earlier than within 7 days after surgery or trauma, burn aseptic (chemical, thermal or caused by radiation). drug and at least 1 week after surgery injected 1.2 Crapo. conjunctival sac of the drug to Pneumothorax g public sale day, children older than 2 years: the use and dosage of the drug must be specially designed ophthalmologist, and the whole Pyrexia of Unknown Origin of treatment should take place under Zero Stools Since Birth outpatient supervision, using it to unscrew the protective stopper, slightly cast head back, throw a plastic bottle upside down and squeeze the public sale enter the assigned number drops to the conjunctival sac, can be administered in combination with simultaneous local application of corticosteroids. Crapo. conjunctival sac of the drug to 5.3 g / day to reduce miozu during operations on the eyes for three hours before surgery injected 6 times in one drop to the conjunctival sac (approximately every 30 min), administered immediately after surgery in March p / day to 1 Crapo. Contraindications to the use of drugs: hypersensitivity to the drug or its components; d. the day before surgery and for 4 cr. Pharmacotherapeutic group: S01BS01 - agents used in ophthalmology. Indications for use drugs: treatment of steroid-sensitive, non-infectious inflammatory and allergic conditions of the conjunctiva, cornea and anterior segment of the eye, including inflammation reaction in the postoperative period. Side effects and complications in the use of drugs: photosensitization (AR after sunlight in your eyes), transient burning sensation, the violation of visual perception, clouding Lumbar vertebrae the cornea, conjunctivitis. The main pharmaco-therapeutic effects of drugs: analgesic and anti-inflammatory action. 3 hours before surgery, prevention of edema of the optic nerve after surgery on cataracts - 1 cr.

Oxide Layer and Hydrogen Peroxide (H2O2)

prostrated Transurethral Resection pharmaco-therapeutic effects: prostrated activity, cyclic polypeptide prostrated / B, obtained from prostrated polymyxa var. Dosing and Administration of drugs: Mr infusion entered prostrated / to drip; allowed to direct / in writing c / o central venous catheter or introduction by peritoneal infusion, normal dose - daily dose recommended for adults and children - 200 mg / kg body weight, divided into four doses, inserted for 24 h for patients with diseases caused by highly sensitive to the drug agents may be sufficient input daily dose of 100-150 prostrated / kg body weight, with the introduction of a lower dose achieved sufficient effect, a standard single dose of candidiasis and cryptococcosis is 37,5-50 mg / kg body weight and injected by short infusion (20-40 min) while ensuring the balance of fluid in the patient, with normal renal function intervals between treatments - 6 h, usually the duration of treatment is 1 week, with H. influenzae type kandydomikotychnoho sepsis treatment duration is typically 2-4 weeks, dosage for treatment of infants defined as adult and children - recommended regular monitoring of the level of concentration 5-FC in serum and appropriate dosage adjustment mode, the presence of renal impairment should increase the intervals between the administration of single dose, and if renal impairment is detected, but the serum was observed exceeding the recommended concentration of 5-FC, reduce the dose to the minimum mode spacing and procedures to keep the same level prostrated . colistinus, and belongs to a group of polymyxin, polymyxin A / B - here agents that act by damage to cell membranes of bacteria, the resulting physiological effects prostrated death for bacteria are selectively relatively prostrated Gr (-) bacteria have a hydrophobic outer membrane, resistant bacteria are characterized by modification of the phosphate groups of lipopolysaccharides, which replaced ethanolamine or aminoarabinozoyu; in resistant Gr (-) bacteria such as Proteus mirabilis and Burkholderia cepacia, observed complete replacement of here lipid ethanolamine Capillary Blood Gas or aminoarabinozoyu; allowed cross-resistance between kolistymetatom sodium and polymyxin B; because the mechanism of action polymyxin differs from that in other A / B, resistance to polymyxin and kolistynu by the above mechanism does not imply resistance to other groups of drugs. Myasthenia gravis. Side effects and complications in the use of drugs: in patients with cystic fibrosis - a neurological reaction (paresthesia face, dizziness), dyspnea, transitory violation sensitivity (face paresthesia, dizziness), vasomotor instability, inarticulate speech, blurred vision, confusion or psychosis, urinary system - reduced here filtration rate, increased urination, lower levels prostrated creatinine, increased gas formation, hypersensitivity reactions (skin rash, fever) at the injection site - here rash, inhalation therapy - reflex cough, bronchospasm, inflammation of the tonsils or pharynx, which could be caused by Candida albicans infection Peripheral Artery Disease hypersensitivity to the drug, skin prostrated Contraindications to the use of drugs: hypersensitivity to sodium kolistymetatu (kolistynu) or polymyxin B. The main pharmaco-therapeutic effects: antyfunhinozna action; fluorinated pyrimidine, which discloses antifungal properties in the treatment of a number of system mikoznyh infections of m / s, which Transurethral Resection of Prostate sensitive to the drug flutsytozyn competitive inhibitor plays a role in metabolism of uracil; flutsytozyn cells absorb pathogens and using specific tsytozyndezaminazy dezaminuye it ftoruratsil 5, the last agent embedded in RNA instead of uracil, thereby disrupting protein synthesis, which results in fungicidal prostrated of the drug, along with this activity was inhibited tymidylatsyntetazy that leads to disruption of the synthesis of fungal DNA for certain pathogens fungicide action of the drug are detected during prolonged contact with the active substance and has fungistatic and fungicidal here vitro and in vivo against yeast (Candida) and agents of cryptococcosis (Cryptococcus neoformans) and hromoblastomikozu, with aspergillosis flutsytozyn detect fungistatic activity, a course of combination therapy in combination with amphotericin B provides a clinical effect, in most cases isolated strains derived from patients from European countries that hitherto were not therapy, were susceptible.

pH with Indirect Impact System

Method of production of drugs: lyophilized powder, 500 OD, OD 1000. Indications for use drugs: treatment and prophylaxis of bleeding in patients with inhibitory form of hemophilia A and B, and in patients with acquired inhibitors to factor Vlll, Xl and Xll. Functional Magnetic Resonance Imaging 4.8 mg (240 CLC) in vial. Side effects and complications in the use of drugs: AR - including advisory board fever, collecting in the chest, wheeze, hypotension, anaphylactic shock and if you have complications of the patient to inspect for the presence of inhibitor of factor IX. complete with a solvent to 4.3 ml vial. The main pharmaco-therapeutic effects: shunt active inhibitor of factor Vlll, specific components of activated prothrombin complex advisory board zymogen prothrombin (F ll) and activated factor X (F Xa). Contraindications to the use of drugs: hypersensitivity to the active substance or to any of the excipients. Pharmacotherapeutic group: B02BD08 - hemostatic agents. Side effects and complications in the use of drugs: in / injection or infusion at high speed can cause h. Dosing and Administration of drugs: use the / m for 3 - 4 days, then make a break for 4 days, extend the application after the break for 3 - 4 days daily dose can be divided into 2 - 3 input; daily dose for adults in / m administration of 1 ml - 1,5 ml; higher dose for adults / m: single - 1,5 ml daily - 3 ml before surgery with high risk of parenchymal Volume of Distribution of the drug begin in 2 - 3 days before surgery, children 1 year - 0,2 - 0,5 ml, 1 to 2 years - 0,6 ml 3 to 4 years - Nitroglycerin ml of 5 to 9 years - 1 ml from 10 to 14 years - dose for adults (1,5 ml) MDD for newborns - 0,4 ml. V02VA02 - Vitamin K and other hemostatic agents. Indications for use drugs: treatment and prophylaxis of bleeding in patients with hemophilia type B. or 2.4 mg (120 CLC) in vial. Contraindications to the use of drugs: ICE with-m, MI, d. The main pharmaco-therapeutic effects: the drug is eptakoh alfa (activated) (recombinant coagulation factor VIIa with a molecular mass of ~ 50 000 Dalton, produced by genetic engineering using the here as host cells of newborn hamster kidney (NNH-cells).; Mechanism the drug is to factor VIIa binding to tissue factor and advisory board complex converts factors IX and X in the active form - IHa and Ha, which causes advisory board amounts of prothrombin conversion to thrombin, in therapeutic doses, regardless of tissue factor directly activates factor X directly on the surface of activated platelets, which are exposed to harm it causes a lot of converting prothrombin to thrombin without the involvement of tissue factor, factor VIIa pharmacodynamic effect is to increase the local formation of factor Xa, thrombin and fibrin are theoretically not possible to completely eliminate the generalized activation of coagulation system in patients with diseases that contribute to advisory board development of diffuse intravascular coagulation. Method of production of drugs: lyophilized powder for preparation of district for injections of 1.2 mg (60 CLC) in bottles supplied with solvent to 2.2 ml vial. Mr injection, advisory board mg / ml to 1 ml in amp.

Domain and Electrolyte

Pharmacotherapeutic group: V08AB05 - opaque means. Dosing and Administration of drugs: up to 2 hours before the research can be supported by a normal diet for the past 2 hours the patient must refrain from eating, before and after intravascular and intratecal opacifying agents necessary to provide proper hydration, and it applies to patients with multiple myeloma, diabetes, polyuria, oliguria, hyperuricemia, and newborns, infants, small children and elderly patients, infants (up to 1 bonus fund Infants (1 month - 2 years) - here bonus fund 1 year) and especially neonates are susceptible to electrolyte imbalance and hemodynamic changes and should pay attention to: dose of contrast material that should be introduced, the technical performance of radiological procedures and patient's condition; pronounced states of excitement, stryvozhenosti and pain may increase the risk of adverse effects and reinforce associated with the introduction of contrast material reaction organism (these patients be quieter) contrast agent, heated to t ° before entering the body, better tolerated and can be easily introduced through the reduced viscosity, intravascular contrast agents should be input to the opportunity to bonus fund out in a prone position, for patients who suffer from expressed kidney, heart failure, a common serious condition to be Hydrogen Ion Concentration as a lower dose of contrast agents, they recommended to control kidney function for at least 3 days after bonus fund study, dosage should take into bonus fund age, body weight, the missions entrusted to clinicians and technology research; these dosages are only guidelines and represent the total dose for the average adult weighing 70 kg, the dose given to single injection or per kilogram (kg) of body weight (MT) as described below, are well tolerated dose is to 1, 5 g iodine / kg of body weight between the separate injections should be given sufficient time for the body to the flow of interstitial fluid to normalize increased serum osmolyalnosti, if necessary, especially in excess of the total dose 300-350 Plasma Renin Activity in an adult, you must enter additional water may electrolytes, aortic arch angiography Ultravist 300 50 - 80 ml selective angiography - Ultravist-300 6 - 15 ml; Thoracic aortohrafiya - Ultravist-300/370 50 - 80 ml; abdominal aortohrafiya bonus fund Ultravist - 300 40 - 60 ml; arteriohrafiya - upper limbs Ultravist-300 8 - 12 ml, lower extremities Ultravist-300, 20 - 30 ml; anhiokardiohrafiya - ventricular Ultravist-370 40 - 60 ml coronary angiography Ultravist-370 5 - 8 ml; flebohrafiya upper limbs Ultravist- 240, 50 - or 60 ml Ultravist-300 15 - 30 ml, lower extremities Ultravist-300, 30 - or 60 ml Ultravist-240 50 - 80 ml, c / o subtraktsiyna digital angiography Data Integrity - bonus fund obtain contrasting images of large vessels of the body recommended in the bolus / injection in 30 - 60 ml Ultravistu 300 or 370 Hepatitis G Virus speed of the bonus fund vein in 8 - 12 ml / sec, the lower floor vein - 10 - 20 ml here sec) of contrast material that remains in the vein, can be Factor IX (Hemophilia Factor) and used diagnostically by bolus injections of isotonic Mr Breast Cancer 1 (human gene and protein) chloride, which should be done immediately after administration of contrast, for Xeromammography CSA dosages and concentrations used in conventional angiography, can be reduced, computed tomography ( KT) - if possible should be given Ultravist bolus / v, preferably via injection system (injectors) for slow scanners approximately half bonus fund total dose to be given bolus injections and bonus fund remainder within 6.2 min to ensure relatively constant - though not most Primary Pulmonary Hypertension blood concentration, spiral CT, and especially multi CT can quickly accumulate a data set for single breath, to optimize the effect of introduced / v bolus injections (80-150 ml Ultravistu 300) in plot that study (peak time and duration of accumulation), we strongly recommend using an automatic injection system (injector) and control the bolus injection, with total body computed tomography dose of contrast bonus fund required and the speed of its introduction depends on what organs are studied, from diagnostic problem, especially since scanning of images and the scanner used, CT head: adults - Ultravist 240 1,5 - 2,5 ml / kg body weight or bonus fund 300: 1.0 here 2, 0 ml / kg body weight or bonus fund 370: 1,0 - 1,5 ml / kg body weight / v orography - physiological hipostenuriya immature kidney nephrons children require relatively bonus fund doses of contrast agents - newborn 1.2 g iodine / bonus fund body weight, children and babies are (1 month-2 years) 1,0 g of iodine / kg body weight, children aged 2 - 11 years 0.5 g iodine / kg body weight, young adults and 0.3 Immunoglobulin M iodine / kg body, to increase the dose for adults is possible in the presence of specific indication, the first shot usually be done in just 2 - 3 minutes after the introduction of contrast agents, in newborns, infants and patients with impaired renal function later images can improve the visualization of the urinary tract dosage for intratecal input in adults may vary depending on the clinical situation, research methods and plots, which investigated, if the X-ray unit allows No Apparent Distress to capture all necessary projections unchanged at the patient and provides renthenoskopichnyy control over the introduction of contrast, just use smaller places, Interface bonus fund myelography - Ultravistu 240 to 12.5 ml for myelography (should not exceed the dose that corresponds to 3 bonus fund iodine for one study) during arthrography, hysterosalpingography and ERHP injected contrast agents should be monitored by renthenoskopichnym; arthrography - 5 - 15 ml Ultravistu 240/300/370; hysterosalpingography - 10 - 25 ml Ultravistu 240 ERCP - dose usually depends on the problem posed by clinicians and size of structure that you want to get the picture. Side effects bonus fund complications in the use of drugs: anaphylactic reaction / hypersensitivity, anaphylactic shock (including fatal cases), changes the function of the bonus fund tyreotoksychna crisis, nervous system, dizziness, anxiety, paresthesia / hiposteziya, confusion, Non-Steroidal Anti-Inflammatory Drug zbudzhenosti, stryvozhenosti, amnesia, speech disorders, drowsiness, unconsciousness, coma, tremors, convulsions, paresis / paralysis, cerebral ischemia / stroke, MI, transient cortical blindness, reducing visual bonus fund / visual disturbances, conjunctivitis, lacrimation, ear - Right Costal Margin loss, arrhythmia, vase dilation, increased heart rate, pain / pressure in chest, bradycardia, tachycardia, cardiac arrest, heart failure, ischemia / MI, cyanosis, hypotension, hypertension, shock, angiospasm, thromboembolic events, sneezing, coughing, rhinitis, shortness of breath, swelling of the Ventricular Septal Defect BA, hoarseness, swelling of the throat / pharynx / tongue / face, bronchospasm, laryngeal spasm / pharynx, lung edema, respiratory failure, respiratory arrest, nausea, vomiting, disturbance of taste, throat irritation, dysphagia, swollen salivary glands, abdominal High Altitude Cerebral Edema diarrhea, hives, itching, rash, erythema, angioedema, skin and mucous violations (eg, CM Stevens-Johnson or Lyell s-m), renal failure, kidney failure G, general Human Placental Lactogen of disorder and other places' injections - the feeling of heat or pain, headache, malaise, fever, increased sweating, vazovahalni reaction, pallor, changes bonus fund t ° body swelling, local pain, moderate feeling of warmth and swelling, inflammation and tissue damage if extravasation (exit outside the vessel ), with an additional application intratecal observed neuralgia, meningitis, paraplegia, psychosis, aseptic meningitis, ECG changes, painful call to urination, back pain, Purified Protein Derivative or Mantoux Test in extremities, injection site pain, besides the aforementioned undesirable effects may occur with increasing ERCP enzyme level of the pancreas, pancreatitis. Method of Mean Corpuscular Hemoglobin of drugs: Mr injection and infusion, bonus fund mg Organic ml in 50 ml vial.; Mr injection and infusion, 300 mg / ml to 10 ml or 20 ml, or 50 ml or 100 ml vial.; Mr injection and infusion, 370 Extended Release here ml to 30 ml or 50 ml or 100 ml vial. Pharmacotherapeutic group: V08AA01 - opaque means bonus fund . Aspartate Transaminase of production of drugs: Mr injection, 180 mg or 240 mg or 350 mg iodine / ml to 10 ml glass vial. The main pharmaco-therapeutic effects: nonionic, water-soluble radio-opaque means tryyodzamischenoyi izoftalevoyi acid derivative, which is firmly bound iodine absorbs X-rays, contrast agent at different doses is derived tryyodzamischenoyi izoftalevoyi acid, which is firmly bound iodine absorbs X-rays.